膀胱癌患者外周血CD4^+ CD25^(high)调节性T细胞

Expression of CD4^+ CD25^(high) regulatory T cells in the peripheral blood of patients with bladder cancer

目的:分析CD4+ CD25high T细胞(Treg)在膀胱癌患者外周血中的分布,初步探讨其临床意义。方法:采用流式细胞术检测59例膀胱癌患者及20名健康人外周血中Treg的比例,探讨其表型特征并分析Treg比例与临床病理特征的关系。结果:与正常对照〔(2.391±1.198)%〕相比,膀胱癌患者外周血中Treg比例明显增加〔(12.429±6.908)%〕,差异有统计学意义,t=3.76,P<0.01;手术后患者外周血中Treg的比例有所下降,与术前比较差异有统计学意义,P<0.05;Treg水平与各临床病理参数之间差异无统计学意义,P>0.05。表型分析显示,Treg高表达CD45RO、HLA-Ⅰ和Foxp3分子,较高水平表达OX40、GITR、CD152、CD95和CD95L,低表达CD80、CD86和CD154分子,基本不表达CD45 RA和CD69分子,HLA-DR的表达水平在个体间差异较大。结论:膀胱癌患者外周血CD4+CD25 high T细胞水平明显升高,可能与肿瘤免疫功能低下及肿瘤发生发展密切相关。

OBJECTIVE：To investigate the prevalence of CD4＋ CD25high T cell in the peripheral blood of patients with bladder carcinoma.METHODS：Flow cytometry was used to evaluate the prevalence of CD4＋ CD25high T cell in the peripheral blood of 59 patient with bladder carcinoma and 20 healthy people.The change of the frequency of Tregs in the peripheral blood of 7 patients before and after operation were investigated.Furthermore,the phenotype of Tregs was determined by flow cytometry too.RESULTS： Compared with normal control（2.391±1.198）%,the prevalence of Treg in the peripheral blood of patients with bladder carcinoma was highly increased（（12.429±6.908）%,t=3.76,P0.01）.After the operation,the frequency of Tregs was decreased（P0.05）.The dependability between the change of Tregs and pathological characteristics was not detected（P0.05）.In addition,the CD4＋ CD25high regulatory T cells had high expression of CD45RO combined with low expression of CD45RA.The costimulatory molecules CD80,CD86 and CD154 could rarely be detected on the surface of Treg cells,whereas Foxp3,HLA-Ⅰwere highly expressed.Some of the Treg cells had variable expression of HLA-DR.The marker of recent activation（CD69） was not found on the surface of Treg cells whereas CD152,GITR,OX40,CD95 and CD95L were expressed on the surface of Treg cells at relatively high levels.CONCLUSIONS： The prevalence of Treg cells is increased in the peripheral blood of patients with bladder carcinoma.These cells may negatively regulate antitumor immune response of patients.